Status:
COMPLETED
Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant
Lead Sponsor:
University Hospital, Brest
Conditions:
Endocrine System Diseases
Osteoporosis
Eligibility:
All Genders
16-75 years
Brief Summary
Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to prevent transplant r...
Detailed Description
Patients \& Methods Inclusion criteria are : patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease; adult and in complete remission at exploration. Exclusion criteria ...
Eligibility Criteria
Inclusion
- patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease
- adult and in complete remission at exploration.
Exclusion
- anteriority of brain radiotherapy
- prior HSCT
- pregnancy
Key Trial Info
Start Date :
November 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 27 2019
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04488432
Start Date
November 27 2019
End Date
November 27 2019
Last Update
September 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest - Endocrinology and Diabetology Department
Brest, France, 29200